BioSpace News Archive

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Walter Flamenbaum , CEO of AgenTus Therapeutics, and Dr. Marc Van Dijk , Chief Technology Officer of Agenus and AgenTus Therapeutics, will participate in

NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the FDA has provided necessary feedback regarding the design of NANORAY-312, the Company’s pivotal phase III global registration trial in head and neck cancer.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, filed suit today against Progenity, Inc. for infringing six patents: U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242 (the “Asserted Patents”). The suit was filed in the U.S. District Court for the Western District of

Oxford University announced yesterday that dexamethasone could reduce deaths in the sickest COVID-19 patients.

Encouraging preliminary results about the iBiopsy® clinical development plan on liver cancer and the technological methods therein Development of a fibrosis biomarker from CT scan imaging A better performing biomarker compared to existing imaging biomarkers

National Health Investors, Inc. (NYSE:NHI) announced today that it will pay its second quarter dividend of $1.1025 per common share on August 7, 2020 to shareholders of record as of June 30, 2020.

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that enrollment in its Phase 2 clinical trial for ELX-02 i

ADVANZ PHARMA Corp. Limitedannounced the voting results from its Annual Meeting of Shareholders held through a virtual meeting platform on June 17, 2020.

OrthoPediatrics Corp., a company exclusively focused on advancing the field of pediatric orthopedics, announced that it is commencing an underwritten public offering of its common stock.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present a company overview at the Bank of America Securities 2020 Napa Biopharma Conference on Wednesday, June 24, 2020 at 10:30 am PT via webcast.